Search Results for “cancer” – Page 158 – media

CRISPR/Cas9 gene editing can be used to eliminate entire chromosomes — a Q&A

As is well known, CRISPR/Cas9 is an effective tool for gene editing, and this method has been widely used for editing genes or genomic regions by targeting specific single-guide RNA (sgRNAs). We initially planned to use the CRISPR/Cas9 system to study the biological functions of Y chromosome genes.
- Source: biomedcentral
- 581
- December 5, 2017
CAS9 chromosome CRISPR gene Researches
Astellas Takes Out Massachusetts’ Biotech Mitobridge in $390M Deal

Tokyo-based Astellas Pharma is buying Cambridge, Mass.-based Mitobridge for a total of $390 million. Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013. Under that deal, the two companies collaborated on discovering and developing drugs that target mitochondrial function. The most advanced program from the collaboration is MA-0211, which is presently in Phase I clinical trials for Duchenne muscular dystrophy (DMD). Astellas is an equity investor in Mitobridge already, and is paying $165.5 million in cash in addition to the $60 million in equity it already owns. There is also an additional $225 million in potential milestone payments. John Carroll, with Endpoints News, writes, “For years now, Salk’s Ron Evans—a celebrated serial entrepreneur in scientific circles—has been concentrating on the potential of a new pathway for turning your average couch potato rodent into Mighty Mouse—without exercise…. A couple of ...
- Source: biospace
- 698
- December 5, 2017
acquisition Astellas Clinical Trials Duchenne muscular dystrophy Market Views Series
When PSA Is 4-10, phi Test Helps With Biopsy Decision

The Prostate Health Index (phi) (Beckman Coulter) significantly changes urologists' opinions about whether men with certain results on prostate-specific antigen (PSA) screening should or should not undergo a prostate biopsy to assess for cancer, according to new observational research.
- Source: medscape
- 815
- December 1, 2017
cancer PSA Researches
Codiak BioSciences Closes $76.5 Million Series C Financing

Codiak intends to use the proceeds of the Series C financing to advance its initial product candidates into clinical trials, and to continue to develop the company's transformational exosome therapeutic platform.
- Source: Businessinsider
- 593
- November 30, 2017
Clinical Trials exosome therapeutic Market Views Series
Radiotherapy-resistant tumors could be defeated with experimental drugs

It may be possible to use drugs that are already in development to overcome radiotherapy resistance in tumors, which is often a major barrier to the successful treatment of many cancers.
- Source: medicalnewstoday
- 538
- November 28, 2017
cancer radiotherapy Researches tumor
Medical Products for Human Use

New technologies, therapies and medicines are emerging; this includes regenerative medicine, more personalised treatments, as well as the development of nanomedicines. The Commission is committed to monitoring scientific progress and to constantly review Community legislation in the light of new developments so as to make safe, novel treatments available to patients as early as possible.
- Source: ec.europa.eu
- 629
- November 28, 2017
nanomedicine polices regenerative medicine
Prometic Reports Positive Interim Clinical Data From Ongoing Intravenous Immunoglobulin Pivotal Phase III Trial

Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced positive interim six-month clinical data from its ongoing pivotal IVIG Phase 3 clinical trial in patients suffering from primary immunodeficiencies (PID) following review of the data by the Data Safety Monitoring Board (DSMB), which confirmed no significant safety issues and that efficacy appeared to be comparable to existing commercial IVIG products.
- Source: Prometic
- 496
- November 28, 2017
Clinical Trials IVIG PID
Unforeseen new drug target discovered for acute myeloid leukemia

A study has found an unexpected new drug target for acute myeloid leukaemia (AML) that could open new avenues to develop effective treatments against this potentially lethal disease. Researchers from the Wellcome Trust Sanger Institute, the Gurdon Institute and their collaborators show that inhibiting the METTL3 gene destroys human and mouse AML cells without harming non-leukaemic blood cells.
- Source: medicalxpress
- 571
- November 28, 2017
AML blood cancer Chemotherapy leukaemia Researches
Roche’s Erivedge no longer funded by the NHS

Roche’s Erivedge will indeed no longer be funded on the National Health Service(NHS) as a treatment for skin cancer after cost regulators issued final guidance ruling that it is not cost effective.
- Source: news.open-medical
- 543
- November 27, 2017
BCC Company Insight Erivedge NHS Roche skin cancer
Investors place bet on Chinese drugmakers

Chinese biotech groups are on target to raise about $10bn this year from venture capital funding, initial public offerings and licensing deals with overseas pharma companies, in what is partly a bet that Chinese-developed drugs can compete globally.
- Source: ft
- 866
- November 24, 2017
China drug innovation pharmaceutical R&D

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.